Transcode Therapeutics, Inc.
RNAZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNAZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNAZ
Transcode Therapeutics, Inc. (RNAZ) is a clinical-stage biotechnology company developing RNA-based therapeutics, with its lead candidate TTX-MC138 in clinical trials for cancer.
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for Transcode Therapeutics, Inc..
Transcode Therapeutics, Inc. (RNAZ) is a clinical-stage biotechnology company developing RNA-based therapeutics, with its lead candidate TTX-MC138 in clinical trials for cancer.
- Lead candidate TTX-MC138 is in clinical trials, with ongoing advancement and additional trials planned [sec_mda · as of 2026-08-14].
- Cash and equivalents of $8.4M as of 2026-06-30, with net income of -$6.8M and shareholders' equity of $10.3M [sec].
- The company expects its cash to support operations through approximately year end 2026, but may require additional capital for continued development [sec_mda · as of 2026-08-14].
- Transcode is heavily dependent on licensed intellectual property and faces risks related to protecting and maintaining those licenses [sec · filed 2026-06-02].
What works
- The company has a proprietary TTX platform that it continues to develop and expand to identify additional product candidates [sec_mda · as of 2026-08-14].
- Transcode is advancing clinical trials with TTX-MC138, its lead candidate, indicating progress in its pipeline [sec_mda · as of 2026-08-14].
What to weigh
- The company has an accumulated deficit of approximately $122.4 million and no product revenue, with profitability dependent on successful development and commercialization [sec_mda · as of 2026-08-14].
- Transcode expects expenses to increase substantially as it advances clinical trials and preclinical studies, requiring additional capital [sec_mda · as of 2026-08-14].
- The company is heavily dependent on licensed intellectual property, and any failure to maintain those licenses could materially affect operations [sec · filed 2026-06-02].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of approximately $122.4 million.
“of approximately $122.4 million.”
SEC MD&A · August 14, 2026
Transcode expects cash to support operations through approximately year end 2026.
“We believe that this cash, along with the proceeds from the sale of the Second Convertible Note, will be sufficient to support our operating expenses and capital expenditure requirements through approximately year end 2026.”
SEC MD&A · August 14, 2026
The company is advancing clinical trials with TTX-MC138.
“advance clinical trials with TTX-MC138;”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- No product revenue — The company has no product revenue and may never generate any, depending on successful development and commercialization [sec_mda · as of 2026-08-14].
- Dependence on licensed IP — Heavy reliance on licensed intellectual property; failure to maintain licenses could harm business [sec · filed 2026-06-02].
- Capital needs — Expects expenses to increase substantially and may require additional capital sooner than expected [sec_mda · as of 2026-08-14].
- Clinical development risks — Success of TTX-MC138 and other candidates is uncertain, with no assurance of regulatory approval [sec_mda · as of 2026-08-14].
What to watch
- Progress of clinical trials for TTX-MC138 and any new data readouts [sec_mda · as of 2026-08-14].
- Ability to secure additional financing to extend cash runway beyond year end 2026 [sec_mda · as of 2026-08-14].
- Developments in the company's proprietary TTX platform and pipeline expansion [sec_mda · as of 2026-08-14].
- Maintenance and protection of licensed intellectual property [sec · filed 2026-06-02].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Transcode Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Transcode Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
5.0 months
OCF -$5M · Net income -$7M
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$249K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 13,090 | $113K |
| geode capital management, llc | 12,740 | $110K |
| vanguard fiduciary trust co | 2,982 | $26K |
| wells fargo & company/mn | 55 | $474 |
| royal bank of canada | 8 | $0 |
Short Interest
as of Apr 21, 2026- % of float
- 5.5%
- Days to cover
- 4.9
- Shares short
- 49,976
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNAZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Transcode Therapeutics, Inc.?
Transcode Therapeutics, Inc. (RNAZ) is a clinical-stage biotechnology company developing RNA-based therapeutics, with its lead candidate TTX-MC138 in clinical trials for cancer.
What is Transcode Therapeutics, Inc.'s lead drug candidate?
Transcode Therapeutics, Inc.'s most advanced tracked candidate is seviprotimut-l (Phase 3) for Adjuvant treatment of patients with Stages IIB and IIC melanoma.
Who is the CEO of Transcode Therapeutics, Inc.?
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. is the chief executive officer of Transcode Therapeutics, Inc. (RNAZ).
Where is Transcode Therapeutics, Inc. headquartered?
Transcode Therapeutics, Inc. (RNAZ) is headquartered in Boston, MA, United States.
What therapeutic areas does Transcode Therapeutics, Inc. focus on?
Transcode Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.